Despite the disappointing results, the higher prevalence rate of MET overexpression than MET gene alterations in lung cancers frequently observed in studies, including the current one, should prompt further refinement of recruiting criteria, such as including measurement of MET phosphorylation level, in future MET targeted therapy trials using MET protein as a selection marker. This evidence concerns the gene MET and lung cancer.